G9D-4 是一种 G9a PROTAC 降解剂,可诱导 G9a 降解并降低 H3K9me2 水平,通过 CRBN 三元复合物、蛋白酶体和类泛素化依赖通路避免 GLP 受到干扰,在胰腺癌细胞中发挥抗增殖活性并诱导细胞凋亡 (Apoptosis),可用于胰腺癌的研究(粉色:EHMT2/G9a/KMT1C 配体 (MS-R80376);蓝色:Cereblon 配体 (MS-Q68284);黑色:连接子)。
产品编号: MS-W23842 CAS No.: 3097803-96-5 分子式: C53H75N9O7 分子量: 950.22
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

G9D-4 是一种 G9a PROTAC 降解剂,可诱导 G9a 降解并降低 H3K9me2 水平,通过 CRBN 三元复合物、蛋白酶体和类泛素化依赖通路避免 GLP 受到干扰,在胰腺癌细胞中发挥抗增殖活性并诱导细胞凋亡 (Apoptosis),可用于胰腺癌的研究(粉色:EHMT2/G9a/KMT1C 配体 (MS-R80376);蓝色:Cereblon 配体 (MS-Q68284);黑色:连接子)。

生物实验数据

生物活性 G9D-4 is a G9a PROTAC degrader that induces G9a degradation and reduces H3K9me2 levels, avoids GLP interference via a CRBN ternary complex-, proteasome- and neddylation-dependent pathway, exerts antiproliferative activity and induces apoptosis in pancreatic cancer cells, and can be used for pancreatic cancer research (pink: EHMT2/G9a/KMT1C ligand (MS-R80376); blue: Cereblon ligand (MS-Q68284); black: linker).
IC50 & Target

Cereblon

 

体外研究
(In Vitro)

G9D-4 (0.008-20 μM;0-24 h) 可在 PANC-1 和 ASPC-1 细胞中诱导 G9a 降解,DC50 分别为 0.1, 0.2 μM,加速 PANC-1 细胞中 G9a 蛋白的降解,且不会改变 GLP 蛋白水平。
G9D-4 (0.04-10 μM;24 h) 降低 PANC-1 细胞中 H3K9me2 的水平。
G9D-4 (1 μM;8 h) 可诱导 PANC-1 细胞中 G9a 降解,该过程需要形成 G9a-G9D-4-CRBN 三元复合物,且依赖类泛素化 (neddylation)-蛋白酶体途径进行。
G9D-4 (72 h) 可抑制一组胰腺癌细胞系 ( KP-4, PANC-1, ASPC-1, HPAF-II, Panc10.05, SW1990, Panc08.13, Panc04.03, Panc05.04, and Panc02.03 cells) 的细胞生长,其 IC50 值范围为 12 至 32 μM,也能抑制 22Rv1 细胞生长,IC50 为 9.9 μM。
G9D-4 (0.1-12.5 μM;24 h) 可在 PANC-1 细胞中诱导细胞凋亡,下调 G9a 和 H3K9me2,同时上调 γH2AX 和剪切型 PARP。
G9D-4 (0-15 μM;72 h) 增强 MRTX1133 (MS-M67046) 对 KRASG12D 突变胰腺癌细胞系 (ASPC-1 cells 和 KP-4 cells) 细胞增殖的抑制作用,协同诱导细胞发生凋亡。
G9D-4 (5-10 μM;10−14 天) 增强 MRTX1133 在 KP-4 细胞中的集落形成抑制活性,对细胞长期增殖表现出协同抑制作用。

Western Blot Analysis

Cell Line: PANC-1 cells
Concentration: 0.008, 0.04, 0.2, 1, 5, 10 μM (dose-response); 1 μM (time-course)
Incubation Time: 8 h (dose-response); 0, 2, 4, 6, 8, 16, 24 h (time-course)
Result: Induced dose-dependent G9a degradation with a DC50 of 0.1 μM. Did not alter GLP protein levels.
Triggered G9a degradation starting after 8 h and continuing through 24 h.
Selectively and dose-dependently reduced H3K9me2 levels.
Induced significant G9a degradation as early as 4 h.

Apoptosis Analysis

Cell Line: PANC-1 cells
Concentration: 5-12.5 μM (24 h); 10 μM (time-course)
Incubation Time: 24 h (dose-response); 12, 24, 48, 72 h (time-course)
Result: Induced significant apoptosis in a dose-dependent manner at 24 h, with ~70% of cells apoptotic at 12.5 μM.
Caused time-dependent apoptosis at 10 μM, with ~60% of cells apoptotic at 72 h.

Western Blot Analysis

Cell Line: ASPC-1 cells
Concentration: 0.008, 0.04, 0.2, 1, 5, 10, 15, 20 μM
Incubation Time: 8 h
Result: Induced dose-dependent G9a degradation with a DC50 of 0.2 μM.
Did not alter GLP protein levels.

Western Blot Analysis

Cell Line: PANC-1 cells
Concentration: 0.1, 1, 10 μM
Incubation Time: 24 h
Result: Dose-dependently reduced G9a and H3K9me2 levels.
Dose-dependently increased γH2AX and cleaved PARP levels, indicating induction of DNA damage and apoptosis.

Cell Proliferation Assay

Cell Line: ASPC-1, KP-4, Panc02.03, Panc10.05, HPAFII, Panc08.13 KRASG12D mutant pancreatic cancer cell lines
Concentration: 30 μM starting concentration, 1.2-fold serial dilutions (ASPC-1); 20 μM starting concentration, 1.2-fold serial dilutions (KP-4); fixed concentrations (co-treated with MRTX1133)
Incubation Time: 72 h
Result: Combined with MRTX1133 showed strong synergistic antiproliferative activity. Had all CI values below 0.8 (ED50, ED75, ED90), with ED90 CI values below 0.4 across all tested cell lines.

Cell Proliferation Assay

Cell Line: KP-4, ASPC-1 cells
Concentration: 5-10 μM (alone); 5-10 μM (co-treated with 1-5 μM MRTX1133, respectively)
Incubation Time: 10-14 days
Result: Alone reduced colony formation. Combined with MRTX1133 almost completely eliminated colony formation, with a significantly greater effect than either single agent.

Apoptosis Analysis

Cell Line: ASPC-1, KP-4 cells
Concentration: 10 μM (co-treated with 1 μM MRTX1133, ASPC-1); 10 μM (co-treated with 5 μM MRTX1133, KP-4)
Incubation Time: 24 h
Result: Combined with MRTX1133 induced significantly higher levels of apoptosis than either single agent.
Triggered ~75% apoptosis in ASPC-1 cells. Triggered ~30% apoptosis in KP-4 cells.

Western Blot Analysis

Cell Line: ASPC-1 cells
Concentration: 10 μM (co-treated with 1 μM MRTX1133)
Incubation Time: 24 h
Result: Combined with MRTX1133 further reduced H3K9me2 levels and significantly increased γH2AX and cleaved PARP levels compared to either single agent.

化学信息

分子量 950.22
分子式 C53H75N9O7
CAS No. 3097803-96-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础